KPMA Warns Of Legal Action Against Korea's April Price Cuts, But It May Be All Talk
This article was originally published in PharmAsia News
Four small companies have initiated lawsuits over pending price cuts, but despite KPMA legal threats, the warning doesn’t appear to be drawing support from larger companies, or from some segments of KPMA.
You may also be interested in...
SEOUL - South Korea's antitrust watchdog the Fair Trade Commission said rebates by both multinational and local Korean pharmaceutical companies are continuing even though doctors can be punished for accepting rebates under a new law that took effect late last year
Multiple IPF drugs are being rushed into Phase III based on early-stage signals of efficacy and safety presented at the ATS meeting. Scrip spoke with the University of Pittsburgh's Kevin Gibson about the candidates, trial design, combination therapy and limitations of current therapy.
Phase III studies testing Dupixent in moderate-to-severe asthma were largely positive, but subgroup details raise questions about how it will compete against biologics targeting the IL-5 pathway. Some experts urge comparison trials to inform physicians' decisions about long-term use.